Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25108944 | 0.88 | SIGMAR1 (0.42) | CHRM4SIGMAR1CARM1PRMT6PRMT1 | |
| SCHEMBL19681559 | 0.83 | NCF1 (0.38) | SIGMAR1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL18389282 | 0.83 | ARG1 (0.37) | ARG1ARG2CHRM4SIGMAR1NOS3 | |
| SCHEMBL10092707 | 0.83 | DRD2 (0.42) | — | |
| SCHEMBL23105099 | 0.83 | ARG1 (0.40) | ARG1ARG2CHRM4CARM1PRMT6 | |
| SCHEMBL8085877 | 0.83 | CARM1 (0.52) | SIGMAR1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8252286 | 0.82 | CYP1A2 (0.40) | CARM1PRMT6PRMT1PRMT8ALDH1A1 | |
| SCHEMBL25075208 | 0.82 | NCF1 (0.39) | SIGMAR1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL1381369 | 0.82 | ARG1 (0.39) | ARG1ARG2CHRM4SIGMAR1NOS3 | |
| SCHEMBL8245487 | 0.82 | NCF1 (0.34) | SIGMAR1CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2022132603-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022087335-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3715343-A1 | DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | ALK, BRAF, MUSK | ARG1 3960/4885ARG2 4594/4885CHRM4 4033/4885 |
| US-20110218175-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | ARG1 295/4885ARG2 926/4885CHRM4 4803/4885 |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | ARG1 2294/4885ARG2 1612/4885CHRM4 4838/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | ARG1 2924/4885ARG2 4655/4885CHRM4 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.